NRx Pharmaceuticals, Inc.

NasdaqCM NRXP

NRx Pharmaceuticals, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2024

NRx Pharmaceuticals, Inc. EPS (Diluted) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

NRx Pharmaceuticals, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -0.47.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqCM: NRXP

NRx Pharmaceuticals, Inc.

CEO	Dr. Jonathan C. Javitt M.D., M.P.H.
IPO Date	Dec. 4, 2017
Location	United States
Headquarters	1201 Orange Street
Employees	2
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Mental Health

Description

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Key trends

Past 5 years